Citation Impact
Citing Papers
Pten Deficiency in Melanocytes Results in Resistance to Hair Graying and Susceptibility to Carcinogen-Induced Melanomagenesis
2008 StandoutNobel
V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway
2009
Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
2012
Development of siRNA Payloads to Target KRAS -Mutant Cancer
2014
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
2008
4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1
2007 StandoutNobel
Similar Nucleotide Excision Repair Capacity in Melanocytes and Melanoma Cells
2010 StandoutNobel
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Microsatellite Instability, Mismatch Repair Deficiency, and BRAF Mutation in Treatment-Resistant Germ Cell Tumors
2009
Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress
2011
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
2009 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Computationally designed sensors detect endogenous Ras activity and signaling effectors at subcellular resolution
2024 StandoutNobel
EGFR Antagonists in Cancer Treatment
2008 Standout
Trametinib (GSK1120212) in the treatment of melanoma
2013
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry
2014 Standout
Short-Term Effects of Nose-Only Cigarette Smoke Exposure on Glutathione Redox Homeostasis, Cytochrome P450 1A1/2 and Respiratory Enzyme Activities in Mice Tissues
2013 Standout
Oxindole synthesis by palladium-catalysed aromatic C–H alkenylation
2010
MEK in cancer and cancer therapy
2013
Transient MEK inhibitor-associated retinopathy in metastatic melanoma
2014
In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml/min is a risk factor for falls and fractures
2005
Targeting the ERK signaling pathway in cancer therapy
2006
Antibody-targeted radiation cancer therapy
2004
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
Trial Watch: Monoclonal antibodies in cancer therapy
2012
Nonalcoholic Fatty Liver Disease
2002 Standout
Clinical experience of MEK inhibitors in cancer therapy
2006
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
BRAF mutation in thyroid cancer
2005
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
2008
Protein Oxidation in Aging, Disease, and Oxidative Stress
1997 Standout
Ras history
2010
Pharmacology of bisphosphonates
2011
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Targeting Mutant BRAF in Melanoma
2012
MAP kinase signalling pathways in cancer
2007 Standout
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
2009
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
2012 Standout
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 Standout
Common pitfalls in preclinical cancer target validation
2017 StandoutNobel
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
2009 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Hematopoietic Stem-Cell Transplantation
2006 Standout
Free radicals and antioxidants in normal physiological functions and human disease
2006 Standout
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
2013
Diabetes impairs the enzymatic disposal of 4-hydroxynonenal in rat liver
2002
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Bisphosphonate-Induced Hypocalcemia: Report of 3 Cases and Review of Literature
2006
Idarucizumab for Dabigatran Reversal
2015 Standout
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Prospects for MEK inhibitors for treating cancer
2014
Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines
2015
The Cross‐Dehydrogenative Coupling of CH Bonds: A Versatile Strategy for CC Bond Formations
2013 Standout
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Targeting the mitogen-activated protein kinase cascade to treat cancer
2004
The PI3K Pathway in Human Disease
2017 Standout
TRPA1 Mediates the Inflammatory Actions of Environmental Irritants and Proalgesic Agents
2006 StandoutNobel
Fate and Effects of Acrolein
1995
MEK Inhibition in the Treatment of Advanced Melanoma
2013
Defining criteria for autoimmune diseases (Witebsky's postulates revisited)
1993
Chronic Kidney Disease
2016 Standout
Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment
2006
Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes
1991 Standout
Guillain-Barré syndrome
2005 Standout
Malignant melanoma: genetics and therapeutics in the genomic era
2006
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
2008
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Copper-Mediated Coupling Reactions and Their Applications in Natural Products and Designed Biomolecules Synthesis
2008 Standout
KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
2009
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Mouse hepatic microsomal oxidation of aliphatic aldehydes (C8 to C011) to carboxylic acids
1992
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Synthesis of Heterocycles via Electrophilic Cyclization of Alkynes Containing Heteroatom
2011 Standout
Synthesis of (2-Oxoindolin-3-ylidene)methyl Acetates Involving a C−H Functionalization Process
2008
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
2008
Cell Surface Antigen and Molecular Targeting in the Treatment of Hematologic Malignancies
2002
Measures of Renal Function, BMD, Bone Loss, and Osteoporotic Fracture in Older Adults: The Rancho Bernardo Study
2006
Transition Metal-Catalyzed Direct Arylation of Substrates with Activated sp3-Hybridized C−H Bonds and Some of Their Synthetic Equivalents with Aryl Halides and Pseudohalides
2009
Trends in Prescription Drug Use Among Adults in the United States From 1999-2012
2015 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Advances in the Chemistry of Tetrahydroquinolines
2011 Standout
National Use of Prescription Medications for Insomnia: NHANES 1999-2010
2014
Conditioning regimens for hematopoietic cell transplantation: one size does not fit all
2014
Transition-Metal-Catalyzed C−S, C−Se, and C−Te Bond Formation via Cross-Coupling and Atom-Economic Addition Reactions
2011 Standout
Estimating Glomerular Filtration Rate in Older People
2014
Targeting Signal Transduction Pathways in Colorectal Cancer—More Than Skin Deep
2005
Ruthenium(II)-Catalyzed C–H Bond Activation and Functionalization
2012 Standout
Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy
2009
Large-Scale Applications of Transition Metal-Catalyzed Couplings for the Synthesis of Pharmaceuticals
2011 Standout
Alendronate Treatment in Women With Normal to Severely Impaired Renal Function: An Analysis of the Fracture Intervention Trial
2007
MEK1 mutations confer resistance to MEK and B-RAF inhibition
2009
Advances in Synthetic Applications of Hypervalent Iodine Compounds
2016 Standout
Synthesis of Stereodefined 3-Alkylideneoxindoles by Palladium-catalyzed Reactions of 2-(Alkynyl)aryl Isocyanates with Thiols and Alcohols
2009
BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications
2007
Heme-Containing Oxygenases
1996 Standout
Assembly of 3-Acyloxindoles via CuI/l -Proline-Catalyzed Intramolecular Arylation of β-Keto Amides
2006
Safety and Efficacy of Risedronate in Patients With Age-Related Reduced Renal Function as Estimated by the Cockcroft and Gault Method: A Pooled Analysis of Nine Clinical Trials
2005
Works of David Mitchell being referenced
Metabolism of the glutathione-acrolein adduct, S-(2-aldehydo-ethyl)glutathione, by rat liver alcohol and aldehyde dehydrogenase.
1989
Relationship between age, renal function and bone mineral density in the US population
2003
Oxidation of aldehydic products of lipid peroxidation by rat liver microsomal aldehyde dehydrogenase
1989
Patient characteristics and patterns of drug use for sleep complaints in the united states: Analysis of national ambulatory medical survey data, 1997–2002
2006
Functional evidence for the recognition of endogenous peptides by autoreactive T cell clones
1989
Effect of renal function on risedronate pharmacokinetics after a single oral dose
2000
Risedronate Pharmacokinetics and Intra- and Inter-Subject Variability Upon Single-Dose Intravenous and Oral Administration
2001
The oxidation of α-β unsaturated aldehydic products of lipid peroxidation by rat liver aldehyde dehydrogenases
1987
Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome
1999
Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies
2005
Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer
2004
Discovery of the Hemifumarate and (α-l -Alanyloxy)methyl Ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH Group
1996